Liposomal nanocarrier delivery system for targeting active cd44 molecule, preparation method therefor, and uses thereof
AssigneeBeijing Inno Medicine Co., Ltd.
InventorsQian Ma, Jiefang Sun
Life of this patent
Estimating the term…
Abstract
A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.
Claims20
A liposome nanocarrier delivery system for targeting an activated CD44 molecule comprising an IL-1 antibody, anti-PCSK9 antibody, adnectin, antisense RNAi oligonucleotide, or nucleic acid, wherein:
- the IL-1 antibody is canakinumab;
- the anti-PCSK9 antibody is evolocumab, alirocumab, bococizumab, RG7652, LY3015014, or LGT-209;
- the adnectin is BMS-962476;
- the antisense RNAi oligonucleotide is ALN-PCSsc;
- and
- the nucleic acid is selected from the group consisting of microRNA-33a, microRNA-27a/b, microRNA-106b, microRNA-302, microRNA-758, microRNA-10b, microRNA-19b, microRNA-26, microRNA-93, microRNA-128-2, microRNA-144, and microRNA-145 antisense strands.
A liposomal nanocarrier delivery system for targeting activated CD44 molecules, characterized in that the surface of the nanocarrier is partially modified by a targeting ligand, and the targeting ligand is a ligand capable of specifically binding to the activated CD44 molecule;
- optionally, other modifications can be made to the surface of the nanocarrier, and the said other modifications are preferably modified on the surface of the carrier with one or more selected form the group consisting of PEG, membrane penetrating peptide, and self peptide SEP, or double ligands modified simultaneously.
Dependencies are inferred from the claim text.